Infliximab–Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies-Reference-Cited by-同舟云学术

Infliximab–Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies

Published:2019-11 Issue:5 Volume:157 Page:1338-1351.e8
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Bar-Yoseph Haggai^ORCID,Pressman Sigal,Blatt Alexandra,Gerassy Vainberg Shiran,Maimon Naama,Starosvetsky Elina,Ungar Bella,Ben-Horin Shomron,Shen-Orr Shai S.^ORCID,Chowers Yehuda

Funder

Leona M. and Harry B. Helmsley Charitable Trust

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference38 articles.

1. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

2. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

3. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review;Gisbert;Am J Gastroenterol,2009

4. Long-term durability of infliximab treatment in Crohnʼs disease and efficacy of dose “escalation” in patients losing response;Chaparro;J Clin Gastroenterol,2011

5. Tailoring anti-TNF therapy in IBD: drug levels and disease activity;Ben-Horin;Nat Rev Gastroenterol Hepatol,2014

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study;Inflammatory Bowel Diseases;2023-06-01

2. Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis;Journal of Inflammation Research;2023-05

3. Association of Antibiotic Use with Durability of Biologic Agents in Inflammatory Bowel Disease: a Report from the epi-IIRN;Journal of Crohn's and Colitis;2023-04-21

4. Epithelial Gab1 calibrates RIPK3-dependent necroptosis to prevent intestinal inflammation;JCI Insight;2023-03-22

5. Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn’s disease;Frontiers in Pharmacology;2023-01-16